| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11510878 | SPIL | Extended release multiparticulates of ranolazine |
Jan, 2038
(13 years from now) | |
| US10898444 | SPIL | Extended release multiparticulates of ranolazine |
Jan, 2038
(13 years from now) | |
Aspruzyo Sprinkle is owned by Spil.
Aspruzyo Sprinkle contains Ranolazine.
Aspruzyo Sprinkle has a total of 2 drug patents out of which 0 drug patents have expired.
Aspruzyo Sprinkle was authorised for market use on 28 February, 2022.
Aspruzyo Sprinkle is available in granules, extended release;oral dosage forms.
The generics of Aspruzyo Sprinkle are possible to be released after 24 January, 2038.
Drugs and Companies using RANOLAZINE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: GRANULES, EXTENDED RELEASE;ORAL
More Information on Dosage
ASPRUZYO SPRINKLE family patents
